Epilepsie Instellingen Nederland Stichting

At Epilepsie Instellingen Nederland Stichting in Zwolle, clinical research focuses on neurological disorders affecting sleep and seizure control. The studies are designed to assess new and existing therapies for improving symptoms, safety, and long-term treatment benefit in people living with complex conditions of the nervous system.

• Narcolepsy and Idiopathic Hypersomnia research aimed at reducing excessive daytime sleepiness and improving daily functioning
• Epilepsy studies in Dravet syndrome, Lennox-Gastaut syndrome, and developmental and epileptic encephalopathies exploring better seizure control
• Trials in refractory focal onset epilepsy evaluating treatment effectiveness and tolerability in difficult-to-manage seizures

Overall, the site is contributing to research on both sleep disorders and rare epileptic conditions, with a strong emphasis on testing therapies that may offer safer and more effective long-term care.

A major part of the clinical trial portfolio at this site centers on narcolepsy and idiopathic hypersomnia. These studies are focused on understanding whether new treatments can lessen excessive daytime sleepiness and support better alertness, energy, and quality of life for patients.

• Narcolepsy Type 1 and Narcolepsy Type 2 treatment research
• Idiopathic hypersomnia studies assessing symptom relief and tolerability
• Clinical evaluation of therapies intended to improve wakefulness in people with persistent sleepiness

This work reflects a broader effort to improve care for people whose daily lives are affected by chronic sleep-wake disorders.

The site also conducts research in epilepsy and related rare seizure disorders, including CDKL5 deficiency disorder, Dravet syndrome, Lennox-Gastaut syndrome, and developmental and epileptic encephalopathies. These trials are aimed at finding therapies that may help reduce seizure burden and support longer-term disease management.

• Studies in CDKL5 deficiency disorder examining seizure control and treatment benefit
• Research in Dravet syndrome and Lennox-Gastaut syndrome focused on safety and effectiveness
• Trials in developmental and epileptic encephalopathies evaluating new options for difficult-to-treat seizures

This area highlights ongoing efforts to improve outcomes for patients with severe and often treatment-resistant epileptic conditions.

Another important research focus is refractory focal onset epilepsy, where studies are assessing whether new therapies can help people whose seizures remain difficult to control. The main purpose is to evaluate treatment effectiveness while also monitoring safety and tolerability in everyday clinical care.

• Research on seizure reduction in refractory focal onset epilepsy
• Evaluation of treatment safety for patients with persistent focal seizures
• Clinical trials exploring better options for people with limited response to standard care

This work adds to the site’s broader neurology portfolio by addressing a challenging form of epilepsy that can significantly affect daily life.